专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2023086799A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS 审中-公开
公开(公告)号：WO2023086799A1
公开(公告)日：2023-05-19
申请号：PCT/US2022/079515
申请日：2022-11-09
申请人： VIGIL NEUROSCIENCE, INC.
发明人： HOUZE, Jonathan B. , PANDYA, Bhaumik , KAPLAN, Alan P.
IPC分类号： A61K31/4725 , A61K31/472 , A61K31/502 , C07D217/22 , C07D237/30 , C07D237/32
摘要： The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

2. 发明申请

WO2022263829A1 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY 审中-公开
公开(公告)号：WO2022263829A1
公开(公告)日：2022-12-22
申请号：PCT/GB2022/051520
申请日：2022-06-16
申请人： Z FACTOR LIMITED
发明人： RAMSDEN, Nigel , FOX, David John , HUNTINGTON, James Andrew , TOMLINSON, James Michael , HEAL, Jonathan Richard , SHERIDAN, Joseph Michael , EARL, Matthew William Mark
IPC分类号： C07D207/263 , C07D209/44 , C07D213/64 , A61P11/00 , C07D213/68 , C07D215/227 , C07D215/233 , C07D231/20 , C07D231/56 , C07D233/70 , C07D237/14 , C07D237/32 , C07D239/36 , C07D239/54 , C07D239/88 , C07D241/18 , C07D241/44 , C07D249/12 , C07D253/04 , C07D253/06 , C07D253/08 , C07D261/12 , C07D263/38 , C07D403/10 , C07D413/10 , A61K31/517 , A61K31/4412 , A61K31/513 , A61K31/5377
摘要： The invention relates to compounds or salts of Formula (I-a), Formula (I-b), Formula (I-c), Formula (I-d), Formula (II) and pharmaceutical compositions containing these compounds. The compounds may be inducers of α1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as α1-antitrypsin deficiency (A1AD or AATD).

3. 发明申请

WO2021225407A1 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도 审中-公开
公开(公告)号：WO2021225407A1
公开(公告)日：2021-11-11
申请号：PCT/KR2021/005738
申请日：2021-05-07
申请人： 주식회사 티씨노바이오사이언스
发明人： 한서정 , 최준원 , 이상희 , 박찬선 , 김성준 , 정재은 , 정희진 , 오도희
IPC分类号： C07D237/32 , A61K31/502 , A61P35/00
摘要： 본 발명은 ENPP1의 억제를 위한 화합물, ENPP1의 억제를 위한 조성물 및 ENPP1의 억제를 위한 방법과 관련된 신규한 프탈라진 유도체 유도체 화합물, 이의 약학적으로 허용 가능한 염, 이의 수화물 또는 이의 입체 이성질체에 대한 발명이다.

4. 发明申请

WO2020047651A1 CD47 BLOCKADE WITH PARP INHIBITION FOR DISEASE TREATMENT 审中-公开
公开(公告)号：WO2020047651A1
公开(公告)日：2020-03-12
申请号：PCT/CA2019/051195
申请日：2019-08-29
申请人： TRILLIUM THERAPEUTICS INC.
发明人： JOHNSON, Lisa Danae Schultz , CUI, Lei
IPC分类号： A61K47/64 , A61K31/166 , A61K31/4184 , A61K31/454 , A61K31/502 , A61K31/5025 , A61K31/55 , A61K38/17 , A61P35/00 , C07C233/65 , C07D237/32 , C07D401/10 , C07D403/04 , C07D471/06 , C07D487/06 , C07K14/05 , C07K19/00
摘要： CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and poly-(ADP-ribose) polymerase (PARP) inhibitor. The CD47 blocking agent can be SIRPαFc and the PARP inhibitor niraparib. The anti-cancer effect of niraparib is enhanced in the presence of SIRPαFc. Specific combinations include SIRPαFc forms that comprise an Fc that is either IgGl or preferably IgG4 isotype. These combinations are useful particularly to treat solid tumours and blood cancers including lymphomas, leukemias and myelomas.

5. 发明申请

WO2018165615A1 PARP-1 AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2018165615A1
公开(公告)日：2018-09-13
申请号：PCT/US2018/021855
申请日：2018-03-09
申请人： THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
发明人： BOULARES, Hamid , GHONIM, Mohamed , AL-KHAMI, Amir , OCHOA, Augusto
IPC分类号： A61K31/502 , A61P35/00 , C07D237/32
摘要： The invention is directed to roles for PARP-1 in disease.

6. 发明申请

WO2017153958A1 NOVEL POLYMORPHIC FORMS AND AMORPHOUS FORM OF OLAPARIB 审中-公开
标题翻译： OLAPARIB的新的多晶型和非晶形式
公开(公告)号：WO2017153958A1
公开(公告)日：2017-09-14
申请号：PCT/IB2017/051407
申请日：2017-03-10
申请人： LUPIN LIMITED
发明人： RAJPUT, Lalitkumar, Dilipsing , SHIVDAVKAR, Radhakrishna, Bhikaji , SINGH, Gurvinder, Pal , RAY, Purna, Chandra , SINGH, Girij, Pal
IPC分类号： C07D237/32 , A61K31/502 , A61P35/00
摘要： The present invention provides crystalline Form M of Olaparib, amorphous form of Olaparib, process for their preparation, pharmaceutical composition thereof and their use as medicaments.
摘要翻译：本发明提供Olaparib的晶型M，奥拉帕尼的无定形形式，其制备方法，其药物组合物以及它们作为药物的用途。

7. 发明申请

WO2017153518A1 PRMT5 INHIBITORS 审中-公开
标题翻译： PRMT5抑制剂
公开(公告)号：WO2017153518A1
公开(公告)日：2017-09-14
申请号：PCT/EP2017/055535
申请日：2017-03-09
申请人： CTxT PTY LIMITED
发明人： STUPPLE, Paul Anthony , WALKER, Scott Raymond , CAMERINO, Michelle Ang
IPC分类号： C07D237/32 , C07D498/08 , A61K31/502 , A61P7/00 , A61P35/00
摘要： A compound of formula (Ia), (Ib) or (Ic) wherein: n is 1 or 2; R N is H or Me; R 1 is optionally one or more halo or methyl groups; R 2a and R 2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH 2 OH; R 2c and R 2d (if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH 2 OH; R 3a and R 3b are independently selected from H and Me; R 4a is selected from OH, -NH 2 , -C(=O)NH 2 , and -CH 2 OH; R 4b is either H or Me; X is either N or CH; R 7 is selected from H and C 1-4 alkyl; (a) one of R 8a , R 8b , R 8c and R 8d is selected from H, halo, C 1-4 alkyl, C 1-4 alkoxy, NHC 1-4 alkyl; (b) another of R 8a , R 8b , R 8c and R 8d is selected from H, C 1-4 alkyl, C 1-4 fluoroalkyl, C 3-6 cycloalkyl, C 5-6 heteroaryl, C 5-6 heteroaryl methyl, C 4-6 heterocyclyl, C 4-6 heterocyclyl methyl, phenyl, benzyl, halo, amido, amidomethyl, acylamido, acylamidomethyl, C 1-4 alkyl ester, C 1-4 alkyl ester methyl, C 1-4 alkyl carbamoyl, C 1-4 alkyl carbamoyl methyl, C 1-4 alkylacyl, C 1-4 alkylacyl methyl, phenylcarbonyl, carboxy, carboxymethyl, ether, amino, amino methyl, sulfonamido, sulfonamino, sulfone, sulfoxide, nitrile and nitrilemethyl; (c) the others of R 8a , R 8b , R 8c and R 8d are H.
摘要翻译：式（Ia），（Ib）或（Ic）的化合物，其中：n是1或2; R N是H或Me; R 1任选地是一个或多个卤素或甲基; R 2a和R 2b独立地选自：（i）F; （ii）H; （iii）我; 和（iv）CH 2 OH; R 2c和R 2d（如果存在）独立地选自：（i）F; （ii）H; （iii）我; 和（iv）CH 2 OH; R 3a和R 3b独立地选自H和Me; R 4a选自OH，-NH 2 2，-C（= O）NH 2和-CH 2，子> OH; R 4b是H或Me; X是N或CH; R 7选自H和C 1-4烷基; （a）R 8a，R 8b，R 8c和R 8d中的一个选自H，卤素，C 1-4烷基，C 1-4烷氧基，NHC 1-4烷基; （b）R 8a，R 8b，R 8c和R 8d中的另一个选自H，C C 1-4烷基，C 1-4氟代烷基，C 3-6环烷基，C 5-6杂芳基，C 5 -C 6杂芳基甲基，C 4-6杂环基，C 4-6杂环基甲基，苯基，苄基，卤素，酰氨基，酰胺基甲基，酰基酰胺基，酰基酰胺基甲基，C 1-4烷基酯，C 1-4烷基酯甲基，C 1-4烷基氨基甲酰基，C C 1-4烷基氨基甲酰基甲基，C 1-4烷基酰基，C 1-4烷基酰基甲基，苯基羰基，羧基，羧甲基，醚，氨基，氨基甲基，亚磺酰氨基，磺酰氨基，砜，亚砜，腈和腈甲基; （c）R 8a，R 8b，R 8c和R 8d其余为H。 p>

8. 发明申请

WO2017061288A1 チロシンホスファターゼ及びチロシンキナーゼ活性の測定方法审中-公开
标题翻译：测定酪氨酸磷酸酶和酪氨酸激酶活性的方法
公开(公告)号：WO2017061288A1
公开(公告)日：2017-04-13
申请号：PCT/JP2016/078224
申请日：2016-09-26
申请人：国立大学法人東京工業大学
发明人：佐藤　伸一 , 中村　浩之 , 中野　洋文
IPC分类号： C12Q1/42 , C12Q1/48 , G01N33/15 , G01N33/50 , C07D237/26 , C07D237/32 , C07K1/113
CPC分类号： C12Q1/42 , C07D237/26 , C07D237/32 , C07K1/113 , C12Q1/48 , G01N33/15 , G01N33/50
摘要：ハイスループット化に適し、高感度の測定方法として、下記の一般式(I)〔式中、Aは共役環を表し、Lは末端に標識物質を有するリンカーなどを表し、R 1 は水素原子など表し、R 2 及びR 3 は、それぞれ水素原子又はアルキル基などを表す。〕で表される化合物を利用したチロシンホスファターゼ及びチロシンキナーゼの活性測定方法を提供する。
摘要翻译：提供了一种测定酪氨酸磷酸酶和酪氨酸激酶活性的方法，作为高灵敏度测定方法，其适用于高通量，并且使用通式（I）表示的化合物（式中，A表示共轭环; L表示在末端具有标记物质的接头等; R1表示氢原子等; R2和R3各自表示氢原子，烷基等）。

9. 发明申请

WO2015086523A1 FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF TNF ACTIVITY 审中-公开
标题翻译：作为TNF活性调节剂的融合双相异构体衍生物
公开(公告)号：WO2015086523A1
公开(公告)日：2015-06-18
申请号：PCT/EP2014/076877
申请日：2014-12-08
申请人： UCB BIOPHARMA SPRL
发明人： ALEXANDER, Rikki Peter , FOULKES, Gregory , HUTCHINGS, Martin Clive , JACKSON, Victoria Elizabeth , KROEPLIEN, Boris , REUBERSON, James Thomas , ROOK, Sarah Margaret , ZHU, Zhaoning
IPC分类号： C07D215/06 , C07D237/28 , C07D237/32 , C07D239/74 , C07D241/44 , A61K31/47 , A61K31/502 , A61K31/517
CPC分类号： C07D239/74 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/502 , A61K31/506 , A61K31/517 , A61K45/06 , C07D215/06 , C07D215/14 , C07D217/16 , C07D237/28 , C07D237/32 , C07D241/42 , C07D241/44 , C07D403/04 , A61K2300/00
摘要： A series of substituted heteroaromatic compounds containing two fused six- membered rings,tivity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
摘要翻译：因此，含有两个稠合六元环的一系列取代的杂芳族化合物（tivity）在治疗和/或预防各种人类疾病（包括自身免疫性和炎症性疾病）中是有益的; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱眼部疾病; 和肿瘤疾病。

10. 发明申请

WO2014113620A3 PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS 审中-公开
标题翻译：苯乙酮和异喹啉类作为岩石抑制剂
公开(公告)号：WO2014113620A3
公开(公告)日：2014-10-09
申请号：PCT/US2014011957
申请日：2014-01-17
申请人： SQUIBB BRISTOL MYERS CO
发明人： GLUNZ PETER W , ZOU YAN , QUAN MIMI L , LADZIATA VLADIMIR
IPC分类号： C07D403/12 , C07D237/32 , C07D401/10 , C07D401/12 , C07D403/10 , C07D405/12 , C07D413/10 , C07D413/12 , C07D417/10 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D513/04
CPC分类号： C07D237/32 , C07D217/24 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/10 , C07D405/12 , C07D413/10 , C07D413/12 , C07D417/10 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D513/04
摘要： The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
摘要翻译：本发明提供式（I）化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性的ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物和使用其治疗心血管，平滑肌，肿瘤学，神经病理学，自身免疫性，纤维化和/或炎症性疾病的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式